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Abstract
The low membrane permeability of candidate drug molecules is a major challenge in drug 
development and insufficient permeability is one reason for the failure of antibiotic treatment 
against bacteria. Quantifying drug transport across specific pathways in living systems is 
challenging since one typically lacks knowledge of the exact lipidome and proteome of the 
individual cells under investigation. Here, we quantify drug permeability across biomimetic 
liposome membranes, with comprehensive control over membrane composition. We integrate the 
microfluidic octanol-assisted liposome assembly platform with an optofluidic transport assay to 
create a complete microfluidic total analysis system for quantifying drug permeability. Our system 
enables us to form liposomes with charged lipids mimicking the negative charge of bacterial 
membranes at physiological pH and salt concentrations, which proved difficult with previous 
liposome formation techniques. Furthermore, the microfluidic technique yields an order of 
magnitude more liposomes per experiment than previous assays. We demonstrate the feasibility 
of the assay by determining the permeability coefficient of norfloxacin and ciprofloxacin across 
biomimetic liposomes.
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3I. Introduction
Over the past decades, multidrug resistance (MDR) in microbial pathogens has developed into 
a serious threat for public health, leading to a global medical crisis1. In 2016, more than half 
(58.6%) of clinical Escherichia coli isolates in the European Union showed resistance to at least 
one of the antimicrobial groups under regular surveillance2. One of the major biochemical causes 
of antibiotic resistance is the reduced membrane permeability of drug molecules3–6. This problem 
is especially apparent for Gram-negative bacteria, as their cell envelope consists of a double 
membrane; drugs require seemingly contradictory chemical properties to overcome these two 
barriers to reach their cytoplasmic targets4,6,7. A deeper understanding of the mechanisms that 
govern passive drug transport across lipid membranes is therefore of great importance. 
Bacterial cell membranes are very complex systems that are involved in numerous cellular 
processes8. Drug permeability studies have not only proven very difficult due to the small size of 
the bacteria, but also due to the convolution of active and passive effects that simultaneously take 
place in the membranes of living bacteria6,9. Many studies on membrane properties are therefore 
performed using lipid vesicles (or liposomes) as model systems9. Liposomes of several microns in 
size, referred to as giant unilamellar vesicles (GUVs), offer the advantages of having well-defined 
lipid compositions, being easy to image and also being more controlled systems for studying 
transport processes than a living bacterium. Due to these advantages, liposomes have been the 
subject of intensive research and their applications now reach far beyond the drug delivery10 and 
synthetic biology communities11–13. 
Various methods to produce lipid vesicles have been developed14. Albeit offering good control 
over lipid composition, many technologies such as electroformation suffer from drawbacks such 
as low yield, batch-to-batch variability, low encapsulation efficiency and polydispersity; these 
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4problems are especially acute at high salt concentrations and when using charged lipids15. 
Microfluidic methods to form liposomes can overcome these limitations, but often require oil as 
the lipid carrying solvent, which must be removed in further procedures16. The recently developed 
microfluidic technique octanol-assisted liposome assembly (OLA) replaces the oil phase with the 
aliphatic alcohol 1-octanol17. A double emulsion of water in octanol self-assembles into a liposome 
with an octanol pocket attached to it upon production. The octanol pocket later pinches off within 
a few minutes, resulting in a liposome and a separated octanol droplet. 
We have previously presented an optofluidic permeability assay which allows us to determine 
the permeability coefficient of electroformed GUVs to fluoroquinolone drugs in a direct, label-
free manner18. The assay exploits the autofluorescence property of fluoroquinolones in the 
ultraviolet for label-free detection. GUVs are exposed to a drug solute in a controlled manner in a 
microfluidic device. We use ultraviolet video fluorescence microscopy to quantify drug uptake in 
the GUVs and report the permeability coefficient of the drug across the membrane composition of 
interest. We used this method to show the influence of lipid composition on fluoroquinolone 
transport19. Furthermore, we showed that the permeability of different drugs from the 
fluoroquinolone family can span over two orders of magnitude at different pH levels20. Finally, we 
used the assay to study the transport behavior of proteoliposomes containing the E. coli outer 
membrane protein OmpF21, thus developing a direct, optical measurement for antibiotic flux 
through porins, which form an important route for drug molecules to translocate across the outer 
membrane of Gram-negative bacteria5. 
Despite these advances, the technique suffered from the various drawbacks of off-chip liposome 
formation described above. In this paper, we present the successful integration of the OLA 
platform with our optofluidic transport assay. This lab-on-chip total analysis platform enables the 
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5continuous production and screening of liposomes on the same device. This enabled us to 
efficiently screen an order of magnitude more liposomes than in our earlier platform. Importantly, 
it also enables us to explore transport using physiological salt concentrations which was 
challenging using electroformed GUVs22. We also present an improved MATLAB analysis 
routine, which offers superior liposome detection, automatic channel recognition and more 
debugging options than our earlier platform. The method was validated by performing transport 
experiments of the fluoroquinolone drugs norfloxacin and ciprofloxacin through biomimetic 
PGPC liposomal membranes. We verified that the liposomes produced are indeed unilamellar by 
performing a dithionite bleaching assay. 
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6II. Materials and Methods
Microfluidic Chip Design
The microfluidic device integrates the channel features used for octanol-assisted liposome 
assembly (OLA) with a downstream T-junction geometry to form a complete lab-on-chip system 
for the continuous production and screening of liposomes. A schematic of the device is shown in 
Fig 1A.
Figure 1. Microfluidic total analysis system for quantifying drug permeability across liposome 
membranes. A: The microfluidic chip features four inlets, one outlet and two different channel 
heights. The outer aqueous, inner aqueous and lipid-octanol inlets are needed for liposome 
production on chip. The fourth inlet is used to flush in the drug whose permeability is to be 
measured. The liposome production occurs at a 6-way junction, where the aqueous flows meet the 
lipid-octanol phase (I). The 1-octanol pocket which is initially attached to the liposome separates 
from it in the post-junction channel within minutes after production (II). After an increase in 
channel height (III), the liposomes are mixed with the drug solute (IV). The transport measurement 
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7takes place as the liposomes flow towards the outlet, immersed in a bath of the autofluorescing 
drug (V). B: Mechanism to separate the liposome population from the octanol droplets. The 
liposomes typically have radii of 15-18 µm upon production and octanol droplets of < 8 µm. The 
channel height post formation is lower than the diameter of the liposomes which leads to a 
significant difference in velocity for octanol droplets and liposomes as indicated by the arrows. 
The octanol droplets pass through the device first and are discarded at the outlet. C: Upon 
production, the liposomes’ diameters are larger than the height of the microfluidic channel. An 
increase in channel height from 16 µm to 35 µm frees the liposomes from the geometric 
confinement and enables transport measurements across the membrane without the risk of shear-
induced leakage.
The 6-way junction where the liposomes are created is shown in Fig. 2A. The design of the 
junction enables the formation of double-emulsion droplets. This leads to the production of a lipid 
bilayer encapsulating an aqueous compartment with a 1-octanol pocket attached to it. The octanol 
droplet then buds off the liposome due to a combined effect of surface energy minimization and 
shear stress induced by the surrounding fluid streams, as well as contact with the channel wall17. 
The original design geometry17 was modified to fit the needs of the drug transport assay. The 
dimensions of the junction were scaled up by a factor of 2 to achieve liposome diameters of up to 
35 µm. The larger channels furthermore lead to higher flow rates and higher liposome production 
rates. A side effect of the larger liposomes and the altered flow conditions is that the budding off 
of the octanol pocket from the liposomes requires more time than for smaller vesicles. The budding 
off process has previously been reported to occur within a minute after production23, whereas this 
process is on the time scale of minutes using our chip geometry. 
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8Figure 2. Liposomes at different positions in the microfluidic chip. A: Liposome assembly at the 
6 way formation junction. A 1-octanol pocket is initially attached to the liposomes. The liposome 
and the octanol pocket separate further downstream in the post-junction channel. B: The liposomes 
experience a spontaneous exposure to a drug solute at a T-junction where the two flows mix in a 
controlled manner. C: The liposomes, surrounded by the autofluorescing drug (λex = 350 nm), can 
be monitored at different parts of the channel, corresponding to different times that the liposome 
has been exposed to the drug. The increase in liposome intensity as the fluorescing drug diffuses 
across the membrane is used to determine the permeability coefficient of the drug across the lipid 
membrane under investigation.
The generated liposomes have diameters larger than the height of the post-junction channel. 
These liposomes therefore initially shear along the PDMS walls, as they flow downstream. To 
ensure that the shear does not compromise the membranes during the subsequent transport 
measurements, an increment in channel height was introduced, increasing the channel height from 
16 µm to 35 µm (Fig. 1C). Post the step, the liposomes flow towards the mixing junction without 
shearing.
Reaching the T-junction, the liposomes are exposed to a drug solute as they flow towards the 
outlet channel (Fig. 2B). Drug transport across the liposome membrane is tracked label-free by 
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9exploiting the autofluorescence of the drug in the UV region (λex = 350 nm). The liposomes 
initially appear dark on a bright background due to the lack of fluorescent drug molecules within 
them. As the fluorescent drug molecules diffuse through the membrane, the liposomes get brighter, 
as seen in Fig. 2C. We record and analyze the increase in fluorescence intensity using a previously 
established analytical protocol to quantify the permeability coefficient of the drug molecule for the 
specific lipid composition under investigation18,20.
Separation of Octanol Droplets and Liposomes Based on Flow Speed
The shearing of the liposomes in the post-junction channel is exploited to separate the liposome 
population from the octanol droplets. This separation mechanism, visualized in Fig. 1B, is based 
on the difference in flow speeds between the liposomes and the droplets. Upon production, the 
liposomes typically have radii of 15-18 µm, whereas the octanol droplets have radii of under 8 µm. 
The channel height of 16 µm before the step causes deformation and shearing of the liposomes 
with the PDMS and slows their flow speed down considerably. In comparison, the smaller octanol 
droplets do not shear and therefore possess a higher velocity. Liposomes typically move with 
speeds of ~0.05 mm/s, whereas the droplets move at ~0.2 mm/s in this region of the chip. We fill 
the post formation channel with the required number of liposomes and subsequently terminate 
liposome formation by reducing the aqueous flows (IA and OA) and stopping the lipid-octanol 
flow (LO) completely. The smaller octanol droplets in the channel get flushed through the mixing 
junction and out of the chip before the larger liposomes reach the junction; the process is possible 
since the surface interactions result in different flow speeds of the liposomes and smaller octanol 
droplets (Fig. 1B). The velocity difference explains the observed separation of the octanol droplets 
and liposomes on chip. After reaching the step, the liposomes are no longer pressed against the 
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channel walls, reconfigure to an expected isotropic spherical geometry and encounter the drug 
flow at the T-junction. 
Chip Fabrication
The microfluidic chips are made of polydimethylsiloxane (PDMS) using established photo- and 
soft- lithography techniques. The master mold is generated by spin coating a thin layer of SU-8 
2025 photoresist (Chestech, UK) on a 4-inch Silicon wafer (University Wafer, USA). The wafer 
is pre-baked on a hot plate at 65°C for 1 min and at 95°C for 6 min. The structures are imprinted 
on the substrate using a table-top laser direct imaging (LDI) system (LPKF ProtoLaser LDI, 
Germany). The LDI system exposes the structures specified in the software directly with UV light, 
causing the photoresist to crosslink and solidify. After exposure, the wafer is post-baked for 1 min 
at 65°C and for 6 min at 95°C. The substrate is developed by rinsing the wafer with propylene 
glycol monomethyl ether acetate (PGMEA), which removes the unexposed photoresist and leaves 
the desired UV-exposed structures on the substrate. The wafer is then hard baked for 15 min at 
120°C. The multi-height feature is achieved by performing this photo-lithography process twice 
on the same silicon wafer with different layers of photoresist with varying heights. Feature heights 
of 16 µm and 35 µm respectively were obtained by spinning the photoresist at 3800 rpm and 1800 
rpm respectively (WS-650-23NPP, Laurell Technologies, USA) for 60 s with a ramp of 100 rpm/s. 
The anchoring tool of the direct laser writer is used for aligning the features in the two designs.
The PDMS microfluidic devices are made by using the silicon master as a mold. Liquid PDMS 
(Sylgard 184, Dow Corning) is mixed in a 9:1 ratio with the curing agent and desiccated to remove 
air bubbles. It is then cast into the mold and cured for 60 min at 60°C. Fluid access ports of 
0.75 mm diameter for the inlets and 1.5 mm diameter for the outlet are punched into the chip using 
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11
biopsy punches (WPI, UK). The PDMS chip is then plasma-bonded to PDMS-coated cover slips 
using a standard plasma bonding protocol (100 W, 10 s exposure, 25 sccm, plasma oven from 
Diener Electric, Germany).
The surfaces of the outlet channel are rendered hydrophilic by flushing the channel with a 
polyvinyl alcohol (PVA) solution for 15 min (50 mg/mL, 87-90% hydrolysed molecular weight 
30,000-70,000 Da, Sigma-Aldrich) via the outer aqueous inlet, using a previously established 
protocol17. Post treatment, the PVA is removed from the channels by applying suction with a 
vacuum pump (Gardner Denver Thomas GmbH, Germany) after which the microfluidic device is 
baked in the oven at 120°C for 15 min.
Optical Setup
The microfluidic chips are either run on a custom-built UV epifluorescence setup, or on a 
commercial epifluorescence microscope (Nikon TE 2000U) to induce autofluorescence in the drug 
molecules and to capture the experimental video data. In the custom built setup, white light from 
a broadband light source (EQ99FC, Energetiq, USA) enters a monochromator (Monoscan 2000, 
OceanOptics, USA) where the excitation wavelength (λex = 350 nm) for the target drug molecule 
is selected. The UV light passes through a Köhler illumination pathway and illuminates the 
microfluidic device via a quad band dichroic mirror (BrightLine full-multiband filter set, Semrock, 
USA) and a microscope objective. The fluorescence signal is detected by an EMCCD camera 
(Evolve 512 Delta, Photometrics). The camera and recording settings (exposure 10 ms, bin 2, 
gain 150) are controlled using the open source software μManager 1.424. A 60× water immersion 
objective (UPLSAPO NA 1.2, Olympus) is used for data recording, whereas lower magnifications 
(4×, 10×, 20×, Plan Achromat, Olympus) are used for optimizing the vesicle formation and PVA 
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treatment of the chip. The Nikon epifluorescence microscope is equipped with a pE-1 LED lamp 
(λex = 365 nm (DAPI), Cool LED, UK) and uses the same water immersion objective, dichroic 
mirror and camera (exposure 15 ms, bin 2, gain 250) as the custom built setup.
Solution Compositions and Flow Control
The base solutions for the OLA aqueous phases consist of 200 mM sucrose and 15% v/v glycerol 
in buffer. In accordance to previously published protocols, the outer aqueous phase additionally 
contains 50 mg/mL poloxamer Kolliphor P-188, which facilitates the initial double-emulsion 
formation23. We performed experiments on the fluoroquinolone drugs norfloxacin and 
ciprofloxacin. Transport of both drugs is measured in phosphate-buffered saline (pH 7.4) which 
mimics physiological pH and salt concentrations. Additionally, experiments using a 5 mM acetic 
acid buffer (pH 5) are performed for norfloxacin as controls for membrane stability. At pH 5, 
norfloxacin molecules are primarily in their positively charged form and hence show low 
permeability through lipid bilayers18,20. The drug solutes are prepared by diluting 48.5 mM 
norfloxacin and 49.5 mM ciprofloxacin stock solutions, respectively, to a final concentration of 
2 mM with the aqueous base stock. All pH levels are adjusted and checked using a digital pH meter 
(Hanna Instruments, UK). The lipid-octanol phase is obtained by dissolving a 100 mg/mL lipid 
stock mixture with 1-octanol to reach a final concentration of 2 mg/mL. The lipid stock is a 3:1 
mixture of DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) and DOPG (1,2-Dioleoyl-sn-
glycero-3-phosphorac-(1-glycerol) sodium salt) in 100% Ethanol. DOPG is an anionic lipid with 
a net charge of -1. Lipid mixtures of DOPG with the net-charge neutral lipid DOPC roughly mimic 
the negative charge density of bacterial lipid extracts and are typically used when modelling 
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bacterial membranes with GUVs25–28. All chemicals are obtained from Sigma-Aldrich, unless 
stated otherwise.
The liquid flows in the microfluidic device are controlled with a pressure-driven microfluidic 
pump (MFCS-EZ, Fluigent). The fluids are stored in Fluiwell-4C reservoirs (Micrewtube 0.5mL, 
Simport) and enter the microfluidic chip via a polymer tubing (Tygon microbore tubing, 0.020’’ x 
0.060’’ OD, Cole Parmer). Cut dispensing tips (Gauge 23 blunt end, Intertronics) are used as metal 
connectors between the tubing and the chip.
Experimental Protocol
The microfluidic assay involves a 2-stage protocol. The first stage involves adjusting the 
pressure-driven flows of the liquids to obtain stable liposome production, as reported previously17. 
Typically, pressures of ~40 mbar for the inner aqueous, lipid-octanol and drug inlet phases, and 
~70 mbar for the outer aqueous phases lead to a stable production of liposomes. After the post-
formation channel has been typically filled with hundreds of liposomes, the aqueous flows are 
reduced (IA and OA input pressures at this stage are typically reduced to around 15 mbar each), 
and the lipid-octanol flow is stopped completely. Due to the difference in flow speeds described 
in Fig. 1B, the octanol droplets flow out of the chip leaving a population of octanol free liposomes 
in the post-formation channel. Throughout the entire process the T-junction is regularly monitored 
to ensure that the drug and OLA flows mix equally and that no octanol enters the drug channel.
The next stage involves the drug permeability measurement, using the same measurement 
principles previously employed in our laboratory18–21. The field-of-view is changed to the channel 
network post the T-junction, shortly after the liposomes encounter the drug flow (Fig. 2C). Using 
a 60× water immersion objective (UPLSAPO, NA 1.2, Olympus), two sections of the channel are 
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monitored simultaneously with sufficient resolution to study the transport process. Since the 
liposome is dispensed in the drug solution flowing along the channel, the different positions in the 
channel correspond to different drug exposure times of the liposome. The IA and OA pressures 
are maintained at 15 mbar each, resulting in flow speeds in the channel of about 0.5 mm/s. One 
measurement is taken just after the drug and the vesicle flows meet (t ≈ 0 s), the other one typically 
after the liposomes have been exposed to the drug for ~15 seconds. Measurements of up to 40 
seconds of drug exposure can be obtained at these flow rates by recording the liposomes at the end 
of the channel network, just before the outlet reservoir. This can be further increased by increasing 
the length of the mixing channel18.
After all the liposomes have been flushed through, the liposome formation can be restarted, and 
the experiment repeated. The number of repeats is limited by the quality of the PVA coating and/or 
accumulation of lipid and octanol aggregates in the chip. The data presented here was obtained by 
performing up to four such repeats on a single chip. However, more repeats are possible and we 
managed to use a chip to perform up to 11 experiments consecutively. Generally, OLA allows for 
continuous liposome production with a frequency of up to 100 Hz for several hours23.
Data Processing and Permeability Calculation
The data is analyzed using our previously established permeability model18–20. The videos 
obtained are processed using a MATLAB routine. Similar to our previously reported analysis 
routine, the script extracts the radius, the speed, the circularity and the intensity values of the 
liposomes passing through the channels. We have updated the image analysis routine, which now 
additionally features superior liposome detection, automatic channel recognition and debugging 
options that are explained in detail in the Supplementary Information.
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The permeability coefficient is obtained by the equation18:
𝑃 =  ― ( 𝑅3𝑡) × ln (∆𝐼(𝑡) ― ∆𝐼(0) + 1)
Where the variable R is the radius of the liposome, t is the time of its exposure to the antibiotic 
and  is the normalized autofluorescence intensity difference between the interior ( ) and the ∆𝐼 𝐼𝑖𝑛
exterior ( ) of the liposome:𝐼𝑜𝑢𝑡
∆𝐼 =  𝐼𝑜𝑢𝑡 ― 𝐼𝑖𝑛𝐼𝑜𝑢𝑡
The difference in the normalized intensity of the liposomes at different drug exposure times can 
be used as a direct readout of drug flux into the liposomes18. Due to the initial lack of fluorescing 
drug molecules inside the liposome, has a high value, correlating to a large difference ∆𝐼(𝑡 = 0) 
in fluorescence intensity between the liposome ( ) and the background ( ). In contrast,  𝐼𝑖𝑛 𝐼𝑜𝑢𝑡  ∆𝐼(𝑡)
at the later time point has a lower value consistent to a lower difference in fluorescence intensity 
between the liposome and the background, due to the influx of fluorescing drug molecules. Further 
explanations and a derivation of the Equations have been published in our previous work18,20.
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III. Results
Test for Membrane Unilamellarity
Liposomes produced by OLA have previously been tested for their unilamellarity via the 
incorporation of the pore forming toxin α-hemolysin17. Additionally, the antimicrobial peptide 
cecropin B was found to permeabilize and lyse OLA-produced liposomes, again suggesting that 
the liposomes are unilamellar28. As an additional, quantitative technique to verify the 
unilamellarity of the OLA-produced liposomes, we extracted the liposomes from our microfluidic 
device and subjected them to a dithionite bleaching assay. If brought in contact with it, the 
membrane-impermeable anion dithionite reduces and thereby irreversibly bleaches 
nitrobenzoxadiazole (NBD). By subjecting unilamellar liposomes containing NBD-labelled lipids 
to a dithionite solution, the fluorescence intensity of the liposome drops to half of the initial value, 
due to the bleaching of the outer leaflet of the bilayer membrane29,30. 
The composition of the inner and outer aqueous solutions used for liposome production in this 
experiment is identical to the solutions of the drug transport assay described above. The lipid-
octanol phase additionally contains 0.01 mg/mL of a fluorescently labelled NBD-PC lipid 
(1-palmitoyl-2-{6-[(7-nitro-2-1,3-benzoxadiazol-4-yl) amino] hexanoyl}-sn-glycero-3-
phosphocholine, Avanti Polar Lipids, USA). A standard PDMS chip with the design shown in 
Fig. 1 is used to extract the liposomes off chip. However, instead of applying a Ø 1.5 mm punch 
at the outlet, a Ø 4 mm hole is punched at the detachment step in this case. The Ø 4 mm outlet 
serves as a fluid reservoir where the liposomes are collected. After the pressures of the microfluidic 
pump have been adjusted to achieve a stable liposome production, an additional 20 µl of the IA 
solution is pipetted into the reservoir, which aids the separation of liposomes and octanol droplets 
in the reservoir. Due to the lower density of octanol, the droplets rise to the surface of the reservoir. 
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A larger fluid volume furthermore facilitates liposome extraction. After 1 hour of liposome 
production, 15 µl of the liposome suspension is extracted from the reservoir using a wide bore 
pipette tip.
The liposome suspension is added to a microscopy chamber (Grace Bio-Labs FlexWell™, 
Sigma Aldrich) on a BSA-coated coverslip containing 35 μl of a solution containing PBS, 200 mM 
glucose and 15% v/v glycerol. The liposomes are left for 1 hour to sink and settle at the bottom of 
the chamber which facilitates imaging. A dithionite solution stock (1M sodium dithionite in Tris 
pH 10 buffer, Sigma Aldrich) is diluted in the glucose buffer to a final dithionite concentration of 
15 mM. 30 μl of the solution is added to the liposome suspension after the imaging is started30. 
Imaging is performed on a confocal microscope (Olympus IX83, FV10-MCPSU laser system, 20x 
objective UPLSAPO Olympus, 5 s frame interval). Image analysis is performed using the open 
source software Image J.
Figure 3. Normalized intensity traces of the liposome membranes. A: Intensity drop of the 
liposome membranes (N = 10) upon addition of dithionite. The mean intensity of the observed 
liposomes is shown in black with the standard deviations depicted in grey. The drop to half of the 
initial value is caused by the bleaching of the outer membrane leaflet by the dithionite. 
B: Liposome intensity (N = 3) stays stable throughout the entire experiment upon addition of buffer 
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without dithionite, suggesting a negligible effect of photo bleaching. The insets show a 
representative liposome at the beginning of the measurement and after 2000 s. The scale bar shows 
10 μm.
The intensity traces of the liposomes normalized to their initial intensity value are depicted in 
Figure 3. Fig. 3A shows the intensity drop upon addition of dithionite, whereas Fig. 3B shows the 
results of the bleaching control experiment upon addition of buffer without dithionite. The mean 
intensity of the observed liposomes is shown as black line with the standard deviations depicted in 
grey. The intensity of the liposomes subjected to dithionite (N = 10) drops to half of the initial 
intensity after about 500 seconds and then stays steady at that value. These results suggest that the 
liposomes indeed consist of a single lipid bilayer, whose outer leaflet is bleached by the 
dithionite29. Since the dithionite anion cannot penetrate the membrane, the inner leaflet of the 
membrane is not affected by the dithionite and remains fluorescent. The control experiment 
without dithionite in Fig 3B shows a stable intensity signal over the timespan of the entire 
experiment (N = 3). This suggests that photo bleaching does not play a significant role in the 
observed drop in the intensity and that we are indeed observing the bleaching of the outer leaflet 
of a single bilayer.
Passive Diffusion Measurements 
Norfloxacin transport measurements were performed in two different chemical environments. 
One set of measurements was performed at physiological pH and salt concentrations (PBS). The 
second set was taken as a control in an acetic acid buffer at pH 5. The majority of norfloxacin 
molecules are positively charged at pH 5 whereas the proportion of uncharged molecules is 
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increased at pH 7.418,20,21,31. The liposomes consisted of PCPG lipids in a 3:1 ratio, a mixture which 
is commonly used as a model for bacterial membranes due to its negative charge25,26.
Figure 4. Norfloxacin diffusion experiments across PCPG liposomal membranes. The scatterplots 
show representative drug uptake experiments at pH 5 and pH 7.4, respectively. Each point in the 
scatter plots corresponds to the measured normalized intensity difference of a liposome. The dark 
points are obtained at t ≈ 0, just after the liposomes encounter the drug flow. The colored points 
show the value at the second measurement position, after exposure to the drug for the time 
indicated in the panel. The gap between the black and red points for the measurement in PBS 
indicates norfloxacin membrane permeability. The histogram shows the distribution of all 
permeability measurements combined at pH 7.4 (N = 1620, 5 technical repeats). The distribution 
has a mean value of 4.13 ± 0.05 x 10-6 cm/s (mean ± std. error of mean) and a median value of 
3.57 x 10-6 cm/s.
The scatter plots in Fig. 4 show representative results from such experiments. The black data 
points mark the normalized intensity difference levels  of individual liposomes at the first ∆𝐼(0)
measurement point, when the liposomes have just encountered the drug flow and hence do not 
contain any drug molecules within them. The colored data points mark the normalized intensity 
difference  of the individual liposomes after they have been exposed to the drug for the time ∆𝐼(𝑡)
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indicated inset. The liposomes in PBS show a substantial drop in  after being exposed to the ∆𝐼
drug, whereas the measurements at the different time points overlap when the studies are 
conducted at pH 5. 
Since the drop in Δ𝐼 is a direct result of the influx of fluorescent molecules, we can conclude 
that no significant transport occurs at pH 5 over the observed timespans, whereas there is 
substantial norfloxacin transport at physiological pH and salt concentrations. The technical repeats 
of this experiment shown in Fig. S3 and Fig. S4 (ESI) report similar results. Expanding the 
exposure and observation time for the pH 5 measurement to 40 seconds yields the same result of 
no significant transport, in line with our previous observations. This also confirms that the 
liposome membranes are not being compromised due to shear or any other interactions in our 
device.
The observed transport behavior is to be expected, as the norfloxacin molecule is predominantly 
uncharged or zwitterionic at neutral pH, whereas the molecule is in a charged state at pH 532. Lipid 
membranes are generally regarded as largely impermeable to ions and highly charged molecules, 
since these cannot cross the hydrocarbon section of the lipid bilayer easily. In nature, these 
transport processes are governed by transmembrane proteins such as porins or ion channels33.
The spread in vesicle radius observed in Fig. 4 is a result of the method used to separate the 
liposomes from the octanol droplet population. As illustrated in Fig. 1B, the mechanism is based 
on a difference in flow velocity in the channel due to shearing of the liposomes. Throughout their 
travel to the step in channel height, the membranes are susceptible to small disruptions due to 
shear. The disruptions can lead to shrinking and separation of the liposomes. This spread in 
liposome size is illustrated in Fig. S2 (ESI). The gradient of the curve that the scatter points lie on 
is a result of the fact that our optical measurement is not a confocal measurement. The fluorescent 
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drug solute surrounding smaller liposomes therefore leads to a lower apparent , compared to ∆𝐼
larger liposomes (for a detailed explanation, please refer to Cama et al.18). The analysis protocols 
are hence identical to our previously established technique.
The resulting permeability coefficients of all the norfloxacin experiments performed in PBS are 
combined in the histogram in Fig. 4. The total number of liposomes in the histogram is 1620 and 
results in an overall average permeability coefficient of 4.13 ± 0.05 x 10-6 cm/s (mean ± std. error 
of mean) and a median value of 3.57 x 10-6 cm/s. The values were obtained from 12 experiments 
in 5 technical repeats. For the pH 5 measurement, five experiments on two technical repeats were 
performed. An experiment is defined as a continuously acquired dataset measured from one batch 
of liposomes produced on the microfluidic device. As described above, up to four experiments 
were performed on one microfluidic device, by restarting the liposome production after completion 
of one measurement. Each set of experiments performed on an individual device is defined as a 
technical repeat. 
The value obtained from the transport measurements matches the values previously obtained in 
our group using the established electroformation liposome production technique. 
Purushothaman et al. measured the permeability coefficient of norfloxacin through PGPC 
liposomes (30:70 ratio) in a 5 mM phosphate buffer solution at pH 7.0 to be 4.3 ± 0.2 x 10-6 cm/s19. 
The main advantages of the on-chip OLA technique over electroformation are the high-throughput 
liposome production and its compatibility with physiological salt concentrations. The higher 
liposome production efficiency allows us to perform tests on 1620 liposomes here compared to the 
138 liposomes in previous experiments using electroformation. Due to the greater efficiency of 
vesicle formation under these conditions and the correspondingly higher number of data points, 
we can provide a more precise estimate of the permeability coefficient than before, with the 
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standard error of the mean lowered by over an order of magnitude compared to the results 
previously reported19 using electroformed vesicles. Furthermore, the possibility of producing 
liposomes at physiological salt concentrations allows us to mimic the natural environment of a 
bacterial cell more closely. Any possible remaining traces of solvent23 (1-octanol, poloxamer 
P-188) do not seem to alter the transport properties of the membrane, as seen by the similarity to 
the previously acquired result.
The scatter plots and histogram of the permeability measurements for ciprofloxacin are 
displayed in Fig. S5 (ESI). The mean (± std. error of mean) permeability coefficient obtained for 
this drug is 4.99 ± 0.07 x 10-6 cm/s and the median value is 4.8 x 10-6 cm/s. The values are obtained 
from 4 experiments (4 technical repeats) and a total of 960 vesicles. The higher permeability 
coefficient of ciprofloxacin compared with norfloxacin is to be expected based on the chemical 
structure of the respective molecules. Norfloxacin carries an ethyl group at the N-1 position, where 
ciprofloxacin has a cyclopropyl group. This functional group is associated with higher lipophilicity 
of the compound and therefore results in a higher permeability coefficient20. 
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IV. Discussion and Conclusion
In this paper, we presented an integrated microfluidic platform for quantifying drug permeation 
across biomimetic membranes. We combined an on-chip liposome formation technique (OLA) 
with a downstream T-junction for the controlled exposure of liposomes to a drug solute. 
Norfloxacin and ciprofloxacin transport through biomimetic PGPC (1:3 ratio) liposomes was 
measured at physiological pH and salt concentrations. The measurements yielded permeability 
coefficients of 4.13 ± 0.05 x 10-6 cm/s (mean ± std. error of mean) with a median value of 
3.57 x 10-6 cm/s for norfloxacin and 4.99 ± 0.07 x 10-6 cm/s (mean ± std. error of mean) and a 
median value of 4.8 x 10-6 cm/s for ciprofloxacin. These values are in good agreement with 
previous measurements19,20. We produced PGPC (1:3) liposomes to mimic the anionic charge 
density typically associated with bacterial membranes25–28, and used this as a model system to 
quantify passive drug transport through the lipid bilayer component of the Gram-negative cell 
envelope. 
Since our method directly quantifies the permeability coefficient of the drug across the specific 
membrane of interest, our technique offers an alternative to traditional drug transport assays such 
as octanol-partition coefficients, or the parallel artificial membrane permeability assay (PAMPA) 
which suffer from multiple drawbacks34,35. Our method also profits from recent advances in the 
development of fluorescent antibiotics, as these provide another potential tool for studying and 
understanding drug transport processes that will lead to further insight into drug-membrane 
interactions36. Importantly, thanks to the microfluidic character of our method, we require only 
very small reagent volumes in the microliter range for our measurements37. 
Another advantage of the integrated on-chip technique presented here over our previously 
published optofluidic permeability assay lies in the benefits of controlling liposome formation with 
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OLA. OLA allows the formation of large numbers of liposomes with physiological salt 
concentrations and with complex lipid mixtures. Other techniques such as electroformation suffer 
from very low yields in this environment15, or in the case of other microfluidic techniques, require 
extensive procedures to remove oil remnants associated with the production17. Moreover, OLA 
allows for the efficient encapsulation of desired solutes inside the vesicles upon production17,27. 
This makes it an interesting technique for biosensor-based approaches to detect drug molecules. 
The encapsulation approach has successfully been performed by Kuhn et al. to measure 
tetracycline transport across lipid bilayers38. However, their experiments were performed using 
populations of small unilamellar vesicles (SUVs) of under 200 nm in radius, whereas we can work 
with GUVs and analyze drug transport on the single vesicle level.
Furthermore, the microfluidic platform presented here is not bound to a specific form of 
visualization such as fluorescence. Since the optics and the microfluidics are decoupled from one 
another, the platform can be combined with different approaches of label-free drug visualization, 
which is a field in its own right with various different methods published39–42. Our platform may 
offer the opportunity to study non-fluorescent molecules in the future.
While passive diffusion across lipids is an important element in bacterial drug uptake, it is known 
that porin-mediated uptake plays a crucial role in drug permeation across the outer membrane7,21. 
Mutations of membrane proteins have furthermore been associated with antibiotic resistance21,43. 
The incorporation of these protein channels into liposomal membranes is an attractive target for 
the study of drug uptake7. However, to integrate this with on-chip liposome formation requires the 
development of on-chip protein reconstitution techniques, which are still pending. The successful 
insertion of the pore forming toxin α-hemolysin into the membrane of OLA generated liposomes17 
suggests that the microfluidic platform can be extended to form and study more complex lipid 
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compositions and even proteoliposomes on chip, potentially offering an alternative to current 
reconstitution techniques44. 
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Associated Content
Complete experimental data set, details on the MATLAB analysis and the spread of liposome 
radius. The MATLAB routine is available on request.
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